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of nonoxynol decreases as the molecular weight in
creases (see Liebert, supra) and that smaller molecular
weight nonoxynol may be more toxic to fibroblasts than

HIGH ENERGY COPRECIPITATE OF
NONOXYNOL OLIGOMER, PVP AND IODINE
HAVING CONTRACEPTIVE AND POTENT
ANTI-HIV PROPERTIES

the larger ones (see Chvapil, M. et al., (1980) Fertil.
Steril. 33: 521-525).
The in vitro spermicidal activity of the N-9 surfactant
is also related to its molecular weight. Thus the oligo

TECHNICAL FIELD
The present invention relates to a composition which

mer n=9 when separated from the N-9 compound, was
much more effective in inhibiting the motility of the
spermatozoa than the higher molecular weight nonox
ynols where n =30, 50, and 100. (See Chvapil, M. et al.,
(1980) Fertil. Steril. 33: 521-525.) The lower molecular
weight nonoxynols (n=1 or 4) could not be studied
appropriately because of their poor solubility in the

is a contraceptive with potent anti-HIV activity. The
composition is a high energy coprecipitate of nonox

ynol oligomers, polyvinylpyrrolidone (PVP) and iodine
and shows a pronounced synergistic effect between the

compounds of the composition.
BACKGROUND
Nonoxynol or nonylphenol(polyethoxy)ethanol is a
nonionic surfactant used as the active ingredient in the

aqueous testing medium (see Chvapil, supra).

majority of the commercially available spermicides. It
inhibits the in vitro growth of venereal pathogens (see
Benes, S. et al., (1985) Antimicrob. Agent Chemother. 27: 20
724-726; Kelly, J. P. et al., (2985), Antimicrob. Agent
Chemother 27: 760-762; Austin, H., et al., (2984) JAMA,
251: 2822-2824; and Singh, B. et al., (1972) Br. J. Vener.
Dis. 48: 57-64), including the herpes simplex viruses (see
Asculai, S. S. et al., (1978) Antimicrob. Agent Chemother. 25
13: 686-690; Hicks, D. R., (1985) Lancet, 1422-1423;
Friedman-Kein, (1986) J. Am. Acad. Dermal. 15:
989-994; RaPP, R- et al., (1985) Antimicrob. Agent’
Chemother. 28: 449-451; Voeller, B., (1986) Lancet,
1153; Malkovsky, M. et al., (1988) Lancet, 645; and
Barbi, M. et al., (1987) Boll. 1st. Sieroter. (Milan) 66:

indicated that increasing the length of the ethylene
oxide chain decreased N-9 oligomer intestinal absorp
tion (see Knaak, J. B. et al., (1966) Toxicol. Appl. Phar
macol. 9: 331-340). Furthermore, data showed that
absorption of N-9 through the vaginal membrane was
poor and re?ects the preferential absorption of lyophilic
low molecular weight oligomers. (See Walter, B. A. et
al. (1988) Toxicol. Applied Pharmacol. 96: 258-268.)
An efficient high pressure liquid chromatography
(HPLC) method for the separation of [14C]N-9 and
characterization of the oligomeric components of the
spermicide N-9 has been developed. (See Walter, B. A.
et a1. (1988) Toxicol. Applied Phannacol. 96: 258-268;
and Walter, B. A. et al., (1991) Phamz. Res. 8: 409-411).
Utilizing this normal phase gradient elution HPLC

158-160).

_

By the nature of its synthesis, the nonoxynol-9 (N-9)
(Igepal CO-630) derivative of nonoxynol is a polymer
consisting of at least 17 oligomers of varying ethylene
oxide (EO) chain length. The molecule of N-9 contains
a hydrophobic moiety (nonylphenol portion) and a
hydrophilic chain composed basically of ethylene oxide

Analogous dependence on molecular weight was
observed in vivo. Oral absorption studies in the rat

method, at least seventeen oligomers were isolated from

commercial N-9. Selected oligomers representing the
high, medium and low molecular weight fraction of N-9
were separated in milligram quantities by normal phase
gradient HPLC (see Waiter, B. A. et al., (1991) Pharm.
Res. 8: 409-411; and Walter, B. A. et al., (1991) Pharm.
Res. 8: 403-408).
Polyvinylpyrrolidone (also known as povidone USP)

units. The compound is a product of a statistical poly
merization reaction of 9 moles of ethylene oxide and

one mole of nonylphenol (see equation below):

is one of the most highly utilized polymers in medicine
because of its safety for human use and unique hydro

0

45

philic properties (see Robinson, B. V. et al. (1990), A
critical review of the Kinetics and Toxicology of Polyvinyl

pyrrolidone, Lewis Publishers, Inc., Michigan).
Discovered and used during World War II as a

plasma expander, PVP is currently used as excipient in
many pharmaceutical preparations intended for external

where “n” represents the number of ethylene oxide

use (e.g. povidone-iodine USP solutions such as Beta
dine); for oral use, such as a solubilizing agent and tablet
disintegrant, and fox vaginal use such as in PVP-I
douche.

units.
The above reaction does not yield a distinct com 55

behavior of drug-povidone coprecipitates. (See Higu

pound but a mixture of oligomers with different molec
ular weights. The physical and chemical characteristics
of these oligomers change as a function of the varying
molecular weight. (See Liebert, M. A., (1983) J. Am.
Coll. Toxicol. 2: 35-60). As the length of the E0 chain
increases, the oligomers increase in water solubility.
Nonoxynol-9 oligomers 1 through 6 (n=1-6) are con
sidered oil soluble compounds, whereas the oligomers
with a longer E0 chain are soluble in water and polar

organic solvents (see Liebert, supra).
These differences in chemical properties of N-9 oligo
mers affect their biological behavior both in vitro and in
vivo. For instance, it was noted that the dermal toxicity

Several studies have focused on the dissolution rate

chi, W. I. et al., (1983) in Proceedings of the International
Symposium on Povidione, Digenis, G. A. and Arisell, J.,

Eds. Lexington, pp. 71-79; Simonelli, A. P. et al., (1987)
in Proceedings of the 2nd International Symposium on
Povidone, Digenis, G. A. and Agha, B. J., Eds., Lexing
ton, pp. 392-401; Simonelli et al., (1969) J. Phamz. Sci,
58: 538-549; Simonelli et al. (1976) ibid. 65: 355-361.)
These studies found that the preferential dissolution
of one component (hydrophilic polymer, such as PVP)
65 can enhance the dissolution of the other component in a

coprecipitate.
Drug/PVP high energy coprecipitates can be de
scribed as a drug incorporated into a solid PVP solu

3
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tion. Drug release from PVP coprecipitates are shown
to follow dissolution kinetics of the polymer carrier of
PVP provided that the PVP solvent uptake or swelling

is enhanced. While PVP alone has no inherent sperm

proceeds freely without inhibition by the drug.
Mayersohn and Gibaldi (Mayersohn M. et al., (1966)

produce a synergistic response which causes a more

spermicides. The above ?ndings concluded that when
N-9 is coprecipitated with PVP its spermicidal activity
toxicity, the formation of N-9/PVP complexes seem to

J. Pharm. Sci. 55: 1323-1324) showed greatly enhanced
dissolution of the antibiotic griseofulvin when the drug
was coprecipitated with povidone (PVP). I-Iiguchi et al.
investigated a povidone/sulfathiazole system and sug
gested that the resultant enhanced aqueous solubility of

rapid damage to the sperm than any of the two materials
alone (Walter, B. A. et al., (1991) Pharm. Res. 8:

403-408).
Nonoxynol-9 (N-9) has been shown to be useful in the

sulfathiazole was due to a high energy state of the drug

prophylaxis against sexually transmitted diseases
(STD). (See Bird, K. D., (1991) AIDS 5: 791-796; and

in the PVP coprecipitate resulting in a supersaturated
form of the drug after introduction into aqueous media.

Louv, W. C. et al., (1988) J. Infect. Dis 158: 518-523).
More recently, this spermicide has been shown to be

(See Higuchi, W. I. et al., (1983) in Proceedings of the

effective against cell-associated HIV at concentrations

International Symposium on Povidz'one, Digenis, G. A.

of 20.05% (v/v). (See Hicks, D. R. et al., (1985) Lan
cet, ii: 1422-1423; Vopeller, B., (1986) Lancet, i: 1153;
and Malkovsky, M., Newell, A., Dalgleish, A. G.,
(1988) Lancet, i: 645).
Unfortunately, N-9 causes epithelial disruption of the
cervix and vagina when administered in high doses and
high frequency (see Niruthisard S. et al., (1991) Sex.

and Ansell, J ., Eds. Lexington, pp. 71-79.)
Simoneill et al., envisioned a PVP/drug coprecipitate

model consisting of two components including the drug
in amorphous state and PVP. (Simonelli, A. P. et al.,

(1987) in Proceedings of the 2nd International Symposium

20

on Povidone, Digenis, G. A. and Agha, B. J., Eds., Lex
ington, pp. 392-401; Simonelli et al., (1969) J. Pharm.
Sci. 58: 538-549; Simonelli et a1. (1976) ibid. 65:

Transm. Dis. 18: 176-179). Higher rates of new HIV
infections were found in prostitutes who used N-9 at

355-361.)

great frequencies (see Kreiss, J. et al., International
The in vitro spermicidal activity of three molecular 25 Conference on AIDS, Montreal, June 1989 [Abstract
weight fractions of N-9 were compared to that of N-9,
MAO36]). This observation was attributed to the high
using rabbit spermatozoa, at equimolar concentrations.
incidence of genital ulceration caused by high doses of
nonoxynol-9/PVP complexes were found to be far
N-9, in this group of women. Thus, the above ?ndings
more effective in immobilizing the sperm than either
tend to suggest that novel spermicide formulations con
N-9 alone or in the separate fractions (Walter, B. A. et 30 taining N-9 should be ef?cacious at the smallest possible

al., (1991) Pharm. Res. 8: 403-408).
The spermicidal activities of three oligomeric frac

doses so that the integrity of the vaginal epithelium is
not compromised.

tions of N-9 with human sperm have been assessed.

The antimicrobia properties of povidone-iodine
(PVP-I), a complex of polyvinyl pyrrolidone and io

Equimolar concentrations of three different molecular
weight fractions of N-9 coprecipitated with PVP were

dine, have been well documented. PVP-I solutions
(10% w/v) USP are among the most widely utilized
for high molecular weight (HMW), (MW=599), 123
antimicrobial agents. A 10% (w/v) solution of PVP-I
pg/ml
for
middle
molecular
weight
contains 1% (w/v) of available iodine (1;). The microbi
(MMW>(MW=499) and 85 ug/ml for low molecular
ological potency of PVP-I arises from the elemental
weight (LMW) (MW: 306) N-9 fractions. The order of 40 (diatomic) or free iodine (12) in solution. The signi?cant
ef?cacy in immobilizing the human spermatozoa was
characteristic ‘of iodophores, such as PVP-I, is that they
35

used. These equimolar concentrations were 166 ug/ml

HMW(MW =599)> MMW(MW =499)>LMW(MW

carry almost all of their iodine in a complexed form so

=306) with complete sperm immobilization observed
with PVP coprecipitated with N-9 HMW within 4.0

PVP-I serves as the iodine reservoir delivering the free

that the amount of free iodine (I2) is quite low and

minutes and PVP coprecipitated with N-9 MMW 45 iodine into the solutions. Thus, iodophors exhibit re
within 15 minutes after exposure. Furthermore, addi
duced irritation properties and are relatively non-toxic
tion of the spermicides interfered with the progressive
(see LaRocca, R. et al., (1983) in Proceedings of the
motility and linearity of the sperm swimming pattern.
International Symposium on Povidone, Digenis, G. A.
PVP and buffer controls showed no decline in percent
and Ansell, J., Eds. Lexington, pp. 101-119).
age motility over the course of the test.

50

Stable, sterile (0.2%) PVP-I compositions containing

Chvapil et al. recognized that the n=9 oligomeric

as little as 0.02% iodine have been shown to be useful in

fraction of nonoxynol-9 was more effective in inhibiting

treating eye infections in humans. A level of 0.02%
iodine obtained byrdiluting a commercial 10% PVP-I
solution at 1:50 with saline solution, is generally consid
55 ered to be optimum to maximize performance and mini

the motility of spermatozoa than the higher molecular
weight nonoxynols. Chvapil et al., however, were un
able to study the lower molecular weight oligomers
(n=l-4) because of their poor solubility in aqueous
media.
In contrast, however, Walter et al. were able to solu
bilize the water insoluble lower molecular weight N-9

mize irritation (see Winicov, M. et al., (1987) in Proceed
ings of the International Symposium on Povidone, Dige
nis, G. A. and Ansell, J., Eds. Lexington, pp. 57-64).
Data has shown that with doubly labeled 1“'C-PVP

oligomers by complexing them with the hydrophilic
polymer polyvinylpyrrolidone (PVP). (See Walter, B.

60 1311 solutions the amount of iodine delivered into gram

A. et al., (1991) Pharm. Res. 8: 403-408.)

The resulting high energy coprecipitate complexes of

positive and negative bacteria cultures was three times
greater when the iodine was complexed with PVP, than

from an equimolar solution of 131I3-—(Lugol’s solution).

the low molecular species of N-9 were found to be at
(See Digenis, G. A. et al., (1983) in Proceedings ofInter
least effective spermicides at all concentrations tested 65 national Symposium on Povidone, Digenis, G. A. and
when compared to their counterparts that were pre
Ansell, J., Eds. Lexington, pp. 302-311).
pared from higher molecular weight N-9 oligomeric
The hydrophilic polymer PVP acts as a delivery
fractions. However, they were themselves effective
system for iodine probably due to the membrane seek

5
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ing properties of this polymer. Ben-David and Gavendo
have shown that PVP at 4.6% w/v concentrations
protect red blood cells from osmotic fragility and me

chanical injury. (See Ben-David A. et al., (1972) Cryobi
ology, 9: 192-197). These workers suggested that this
effect is brought about by a “coating” or external inter
action of PVP with cell membranes.

6

prevent the transmission of venereal diseases, possibly
including AIDS.
U.S. Pat. No. 4,707,362 to Nuwayser discloses a sus

tained release composition made of synthetic polymers
5 such as polyvinylpyrrolidone. The bioerodible material
in one embodiment has been modi?ed so that a spermi

The membrane-seeking properties of PVP suggest
that in addition to its contribution to the solubilization

cide such as nonoxynol-9 is slowly released. Nuwayser
does not disclose PVP-I in combination with nonox

ynol-9.

ability of N-9, the PVP polymer, via its cell-membrane 10 U.S. Pat. No. 4,954,351 to Sackler et al. discloses a
coating properties, also provides vaginal and cervical
method of producing standardized povidone-iodine
surface coverage coating with N-9 and iodine over
preparations. The patent discloses that the povidone-io
extended periods of time.
dine solution can be incorporated into a suppository
In addition to its antimicrobial properties, PVP-I has
with 0.1 to 10% by Weight of povidone-iodine. Sacklet
been shown to inactivate HIV. (See Kaplan, I. C. et al. 15 et al. do not disclose the use of povidone-iodine in com
bination with nonoxynol-9.
(1987) Infect. Control 8: 412-424; and Harbison, M. A. et
U.S. Pat. No. 4,297,341 to Waller et al. discloses that
al., (1989) J. Acquir. Immune De?c. Syndr. 2: 16-20).
The concentration of iodine used in Kaplan’s studies
a water-soluble complex comprising polyvinylpyrroli
was equal to 0.025% for 250 ppm of 1;.
done and gossypol is an effective spermicide. The pa
A 0.02% w/v (200 ppm) solution of iodine is consid 20 tent discloses that a PVP-gossypol combination when
ered non-toxic and non-irritating and is used for treat
compared to a comparative example of nonoxynol-9
ment of eye infections in humans. (See Winicov, M. et
alone, exhibited equal or greater spermicidal properties.
al., (1987) in Proceedings of the International Symposium
Waller does not disclose PVP-I in combination with
nonoxynol-9.
on Povidone, Digenis, G. A. and Ansell, J ., Eds. Lexing
25
ton, pp. 57-64). In fact, the increased bactericidal activ
U.S. Pat. No. 4,925,033 to Stoner et al. discloses a
ity of dilute solutions of povidone-iodine (Betadi
microbicidal cleanser/barrier kit. One method of the
invention involves applying a solution of povidone-io
ne—l0% w/v PVP-I) have recently been well docu
mented. Betadine contains 10,000 ppm (or 10,000
dine (PVP-I) to vaginal sponges or condoms. In another
[lg/ml) of available iodine and is often irritating to the 30 embodiment the povidone-iodine active ingredient may
tissues and has an undesirable brown color. (See Berkel
be added to spermicidal birth control compounds.
Stoner et al. disclose that nonoxynol-9 is a known sper
man, R. L. et al., (1982)]. Clin. Microbiol. 15: 635-639.)
At concentrations of about 0.02% w/v of iodine, the
micidal compound. Stoner et al. do not disclose or sug
undesirable brown color of iodine is not a problem since
gest the particular combination of components in the
in dilute solutions the color is hardly seen and the 35 form of a high energy coprecipitate, nor that the com
amount of iodine is not irritating to tissues.
pounds show a synergistic anti-HIV effect.
None of the prior research in this area recognized the
Heterosexual transmission of human immunode?
synergistic anti-HIV result of all three compounds
ciency virus (HIV), the causative agent of AIDS, is a
when formulated into a high energy coprecipitate.
growing concern in the United States where 37% of
Furthermore, spermicides containing nonoxynol-9 AIDS cases are heterosexually transmitted, the major
and polyvinylpyrrolidone or polyurethane are known.
U.S. Pat. No. 4,317,447 to Williams discloses a device

ity being male-to-female. Moreover, the frequency of
global heterosexual transmission is probably greater

for delivering a medicament to the vaginal cavity con
where it is estimated to exceed 60% of all AIDS cases.
sisting of a molded sheath of a mixture of a polymeric
It has been suggested that a major contributing factor
material and a medicament. The medicament which is 45 to heterosexual transmission of HIV is the presence of

dispersed in the polymeric material can be nonoxynol-9.
The polymer may be selected from modi?ed cellulose,

cell-free virus and virus-infected cell (cell-associated

polyvinyl alcohol, polyvinylpyrrolidone, polyacrylic

which inactivate HIV should be an effective barrier to

and ethylene oxide polymer. Williams does not disclose

transmission.

virus in genital secretions. Thus, vaginal contraceptives

the use of PVP-I in combination with a nonoxynol-9. 50
There is a need in the pharmaceutical area for a a
contraceptive with potent anti-HIV activity. Ideally, a
U.S. Pat. No. 5,156,164 to LeVeen et al. discloses that

iodine can be dissolved in alcohol containing nonoxynol
contraceptive agent is needed that can:
in a complex with polyurethane. LeVeen et al. disclose
la) provide rapid spermicide delivery (within 30-60
that a polyvinylpyrrolidone-iodine complex has been
seconds);
effective in treating resistant vaginitis. LeVeen et al. do 55
lb) provide long-actingsperrnicidal activity after a
not disclose or suggest combining PVP-I with nonox

ynol.
U.S. Pat. No. 5,070,889 to Leveen et al. discloses a

contraceptive sponge and tampon made of polyure
thane iodine complex. Leveen et al. teaches away from
the use of povidone iodine or use as a contraceptive.

U.S. Pat. No. 5,073,365 to Katz et al. discloses clinical
and personal care articles enhanced by lubricants and
adjuvants. The devices can be made of polyvinylpyrrol
idone or polyurethane interpolymers. The device may 65

single application;

2) protect the user against HIV (AIDS) and other
sexually transmitted diseases (STDs);

3) protect vaginal and cervical epithelia from irrita
tron;

4) enhance penetration of spermicide into cervical
mucus;

5) exhibit low systemic bioavailability (low absorp

tion);

6) be pharmaceutically and cosmetically acceptable

take the form of vaginal diaphragms, tampons, condoms

(e.g. a tablet or capsule are preferred, as supposito

or cervical caps. The medicament may be nonoxynol-9.
Katz et al. disclose that the personal care articles may

ries, creams and gels appear not to be as attractive

to young users).

7

5,380,523

The composition of the invention meets the above

objectives and provides a high energy coprecipitate of

nonoxyno1-9 oligomers, polyvinylpyrrolidone and io
dine (PVP-I). The composition shows a pronounced
synergistic effect between the compounds which results
in potent anti-HIV activity. The composition of the

5

preparation and assessment of new chemical entities

ceptive with potent anti-HIV activity.

oligomers, small amounts of iodine (l2) and the hydro

Disclosure of the Invention
It is an object of the invention to provide a novel and

philic polymer PVP in such a way as to form high

energy complexes, also known as coprecipitates.
The novel contraceptive composition of the inven
tion comprises a high energy coprecipitate made from
N-9 oligomers, PVP and iodine. A pronounced syner
gistic effect is obtained between the compounds, en
hancing the anti-HIV activity of the compounds when
in the form of a coprecipitate. Due to the synergistic
effect of the compounds present in the high energy
coprecipitate, the coprecipitate requires less of each of
the individual ingredients to achieve the desired anti

potent contraceptive and/or spermicide possessing pro
nounced anti-HIV properties which is a high energy

coprecipitate composition comprising N-9 oligomers
and PVP and iodine. The PVP and iodine ingredients
may be present in the coprecipitate composition as the

complex PVP-I.
The invention further provides a high energy copre
cipitate composition which is in the form of a powder.
In a preferred embodiment the invention provides a

HIV result, than if the compounds were to be adminis

high energy coprecipitate composition including PVP-I

tered as a mixture. This is bene?cial as it reduces irrita

which comprises about 0.09-9% W/w of iodine.
In yet another embodiment, the invention provides a
high energy coprecipitate composition of N-9 com
plexed with PVP‘ comprising an antiviral concentration

tion to tissues caused by higher doses of N9 and iodine
and thus reduces the potential for HIV virus transmis
sion.

The high energy coprecipitates of the invention are

of free iodine of about 0.03% w/v or about 300 ppm.

formulated by fractionating commercially available

The invention additionally provides a high energy
coprecipitate composition of N-9 complexed with PVP

spermicide, N-9, into seventeen oligomers by a prepara

tive high pressure liquid chromatography (HPLC) pro

comprising an antiviral concentration of free iodine
providing about 9.4 to 0.09 % I2 providing an effective

cedure. Selected oligomers of N-9, or the commercially
available N-9, are converted to high energy coprecipi

concentration of free iodine of 0.0094% w/v (94 ppm)

tates with PVP and various amounts of iodine (PVP-I).
In a preferred embodiment the amount of iodine is
about 0.09-9% w/w of iodine. The content of N-9 in

and from about ‘11.8 —5.8% w/w of N-9 providing an

effective concentration of N-9 of 0.0058% w/v (58
In a further embodiment, the invention includes a

DESCRIPTION OF THE INVENTION
The present invention describes methodology for the

with pronounced spermicidal and anti-HIV properties.
These chemical entities incorporate N-9 or selected N-9

invention safely and cost-effectively provides a contra

ppm)

8

and may take the form of an elegant, free ?owing pow
der.

35 the above complexes, in a preferred embodiment,

ranges from 5.8-12% w/w.
N-9 and its oligomeric components are inherently
viscous liquids which are converted to free ?owing,

high energy coprecipitate composition comprising an

effective ?nal concentration of from about 4-200 pg/ml
of N-9.
water soluble powders by forming coprecipitates with
The invention advantageously provides for a method 40 PVP-I. Several combinations of iodine (I2), N-9 and
of preparing a high-energy coprecipitate composition
PVP are utilized to produce powders which exhibit a

comprising the steps of:

variety of spermicidal and anti-HIV activities.

(a) fractionating commercially available spermicide

In order to test and compare the anti-HIV activity of

N-9 to seventeen oligomers by a preparative high

pressure liquid chromatography (HPLC) proce

45

dure; and
(b) converting the oligomers or commercially avail

the high energy coprecipitates of the invention, the
following assay procedure was performed.
Procedure for Anti-HIV Activity Assessment

able N-9 to a high energy coprecipitate with PVP
High-titer suspensions (>106infectious particles/ml)
and iodine.
were incubated with each compound for 5 seconds,
Preferred is a method of preparing a high-energy 50 then immediately diluted 1:50 onto cultures of human
coprecipitate composition including the steps of:
MT-2 cells for detection of infectivity. Cellular toxicit

(a) fractionating commercially available spermicide
nonoxynol-9 (N-9) to seventeen oligomers by high

pressure liquid chromatography (HPLC);
(b) adding an N-9 oligomer obtained in step (a) with
a 10% or 1% solution w/v of PVP-I in a solvent,

(c) placing the product of step (b) in an oil bath at
about 100° C., and allowing the solvent to evapo~
rate.

(d) obtaining a high energy coprecipitate of N-9,
polyvinylpyrrolidone (PVP) and iodine.
Also included is a method of treating a female com
prising administering to a female an effective amount of

a high energy coprecipitate comprising N-9 oligomers,

ies were observed and no antiviral activities were ex

pected after the 1:50 dilution, hence all antiviral activity
would have resulted from the 5 second exposure. Infec

tions were monitored by syncytium (giant cells) forma
tion and Immune Fluorescence Assay (IFA). This assay
utilizes all antiviral antibody with a ?uorochrome at
tached to it through a covalent bond. Virus particles get
to ?uoresce when viable, and therefore the degree of

infectivity is quantitated.
The results after 3, 5 and 8 days of incubation are
shown in Table 1. In the control experiment, using the
untreated virus, the MT-2 cells are 100% infected at the

PVP and iodine to achieve a contraceptive and anti 65

end of 3 days.
A 1% value or less, indicates a complete inactivation

HIV environment in the vaginal cavity. Thus, the in
vention provides spermicidal and anti-HIV activity

of the virus as measured by the IFA method, i.e. no
?uorescent particles of the virus exist inside or outside

with no irritation to the cervical and vaginal epithelia,

the cells (Table l).

5,380,523
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Syncytia (giant cell) formation is assessed by staining
techniques with subsequent microscopic examination.

cell-associated HIV-1. This represents approximately

Syncytia formation indicates invasion of the MT-2 cells

0.12% w/v of free iodine (or 1,200 ppm of 12).

an effective concentration of 1.2% w/v of PVP-I or

by the virus.

A solution was made from a PVP—I and N-9 high

The method described is that of Montefiori et al.

energy coprecipitate. The coprecipitate composition

“Evaluation of Antiviral Drugs and neutralizing anti
bodies to human immunode?ciency virus by a rapid and
sensitive microtiter infection assay”, J. Clin. lllicrobiol.

concentration of 3.24 mg/ml of PVP-I and 0.2 mg/ml of

1988, Vol 26: 231-235, incorporated herein by refer
ence.

was 94.2% w/w of PVP-I and 5.8% W/w of N-9, at a
N-9 of an average molecular weight of 599. This com

position achieved a complete eradication of the HIV
10 virus in 30 seconds.

Table 1 summarizes the results of anti-HIV activity
assessment of two high energy coprecipitate powders of

The use of high molecular weight N-9 oligomers as a

component of the anti-HIV coprecipitate composition
decreases the systemic absorption of N-9 and therefore

PVP-I and N-9. The ?rst was made with oligomers of
N-9 with an average molecular weight of 599 and the
N-9 is localized in the vagina and less toxic to the fe
second with the oligomers of N-9 with an average mo 15 male.

lecular weight of 306. Both samples were coprecipi

Similar anti-HIV results were obtained with a copre

tated with PVP, iodine and one of N-9 oligomers men
tioned above.

cipitate of about 5.8 mg/ml PVP-I and about 0.2 mg/ml

TABLE 1
Inactivation of Cell-Free and‘ Cell-Associated HIV-11
3 days
5 days
8 days
DRUG
Syncytia IFAZ Syncytia
IFA
IFA
PVP

+++

>80%

cm;3

CPE

CPE

+++

> 80%

CPE

CPE

CPE

-

10%

+ ++

> 80%

CPE

+++

> 80%

CPE

CPE

CPE

(11.8 mg/ml)
PVP

(0.236 mg/ml)
PVP

N-9 of an average molecular weight of 306. These re
sults represent an antiviral concentration of free iodine
20 of about 0.03% w/v (324 ppm). This level of iodine is

not irritating to the vaginal epithelial tissue and desir
ably has no noticeable brown color.
In contrast to the above results, when no iodine is
present in a coprecipitate composition made with 94.2%
25 w/w of PVP and 5.8% w/w of N-9, at a concentration
of 3.24 mg/mL of PVP and 0.2 mg/mL of N-9 of an

average molecular weight of 599, the antiviral proper
ties of the product were substantially reduced (see

(3.24 mg/ml)
high MW N-9

Table 1).

(0.2 mg/ml)

(0.0648 mg/ml)

A similar reduction of the antiviral properties was
also observed when the product was made from a

high MW N-9

PVP/N-9 high energy coprecipitate of 94.2% w/w of

PVP

30

(0.004 tug/ml)
PVP

10%

+++

> 80%

PVP and 5.8% w/w of N-9, at a concentration of 3.24

CPE

mg/mL of PVP and 0.2 mg/mL of N-9 of an average

(5.8 mg/ml)
10W NW N-9

35

(0.2 mg/ml)
PVP

+++

> 80%

CPE

CPE

molecular weight of 599 (see Table 1).
Thus, in a preferred embodiment, the presence of 324
ppm iodine in the case of high molecular weight (599)

CPE

(0.116 mg/ml)
low MW N-9

N-9. and 580 ppm of iodine, in the case of the lower

(0.004 mg/ml)

molecular weight N-9 (306) importantly adds to the
synergistic anti-HIV effect of the high energy coprecip

PVP-I

(11.8 mg/ml)
PVP-I

+++

> 30%

+++

<1%

CPE

CPE

CPE

<l%

0%

itate. The iodine and N-9 both act in a synergistic man

ner when complexed with PVP.
Other solutions made from PVP-I and N-9 coprecipi
tate in accordance with the invention include 94.2% of

(0.236 mg/ml)
PVP-I

(3.24 mg/ml)
high MW N-9

45 PVP-I and 5.8% of N-9 with an average molecular

(—)
(0.2 mg/ml)
PVP-I

+++

> 80%

CPE

CPE

CPE

CPE
<1%

CPE
0%

CPE

CPE

weight of 599. A further solution made from PVP-I and
N-9 coprecipitate comprises 94.2% of PVP and 5.8% of
N-9 with a weight average molecular weight of 306.
The chemical union of the iodine, PVP and several

(0.0648 mg/ml)
high MW N-9

(0.004 mg/ml)
PVP-I

CPE

+++
-

50

(5.8 mg/ml)
low MW N-9

(0.2 mg/ml)
PVP-I

> 80%

CPE

immunode?ciency virus (HIV) (Tables 1 and 2).

(0.116 mg/ml)
low MW N-9

(0.004 mg/ml)
+++
1Details of experimental procedures are given in the test.
1% IFA positive cells
3CPE, viral-induced cytopathic effect was complete.
HMW N-9 = 599
LMW N-9 = 306

The data in Table 1 show that PVP-I at a concentra

tion of 11.8 mg/ml completely inactivated cell-free and

oligomers of the spermicidal agent N-9 with different
molecular weights results in an impressive synergistic
action of iodine and the spermicide N-9 against human

55

The coprecipitate of the invention shows that the
synergism between iodine and N-9 is of such magnitude
that solutions with even smaller concentrations of these
species can be used. Again, this is bene?cial as it reduces
vaginal irritation and thus reduces the potential for HIV
virus transmission. Indeed, a complete eradication of
the HIV-virus was obtained when coprecipitates of
PVP, iodine and N-9 solution, containing as low as 58
ppm of N-9 and 940 ppm of PVP-I (94 ppm of iodine),
were utilized (see Table 2).

TABLE 2
Concentration on Virus

IgglmL = ppm|

Syncytia

IFA Position

5,380,523
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TABLE 2-continued
Compound

N9

PVP-I

%

No drug

—

—

100

100

58
117.4
118

940
10
0

0
10
30

0
s
10

KYO48
101050
KY052

Cells %

compggition of KY Coprecipitates

KY048
KYOSO
KY052

PVP
%
ppm

%

PVP-I
ppm

0
0
88.58 885,800
88.20 882,000

94.20
0.90
0

940,000
9,400
0

12
%

9.40
0.09
0

N-9
ppm

%

ppm

94,000
940
0

5.80
10.52
11.8

58,000
105,200
118,000
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The synergistic effect against the HIV is so signi?

The following examples are given to illustrate the
invention, but are not to be construed as limiting.

cant that the above PVP-I/N-9 solution at concentra
tions as small as 58 ppm of N-9 and 94 ppm of iodine are

EXAMPLE 1
The various compositions of coprecipitates are made

effective, against the HIV virus (Table 2).

In addition to the unexpected synergism between the 20 according to the following general procedure: Stock
compounds, the coprecipitation of iodine, N-9 and PVP
solutions of approximately 1% w/v of PVP-I and 1%
results in the formation of freely ?owing powders
w/v N-9 are made in ethanol or methanol.
which enable the preparation of elegant solid pharma
The N-9 stock solution is added dropwise to an ali
ceutical formulations with control release properties.
quot of the PVP-I stock solution with stirring. It is
The coprecipitate powders are particularly useful in the 25 critical that the two solutions are mixed at a very slow
design of acceptable solid formulations intended for
rate. Thus, the introduction of the N-9 solution, into the
vaginal, or other appropriate use.
round bottom ?ask, containing the PVP-I, must be done
The coprecipitate composition may be administered
dropwise but over a period of not longer than 1.5 hours.
in the form of solid formulations, such as tablets or
Subsequently, the solvent is evaporated from the
capsules, or as ointments, creams or suppositories. In a 30 PVP-I/N-9 solution by heating in a preheated oil bath
preferred embodiment the composition is administered
at 100° C. The temperature must be kept constant at
in the form of a capsule or tablet.
100° C. The evaporation process should last between
Tablets, capsules, ointments, creams or suppositories
l-2 hours but no longer than two hours.
may be formulated according methods known in the art
such as those disclosed in Remington’s Pharmaceutical 35

Science, 18th Ed. pp. 1602-1712, incorporated herein by

EXAMPLE 2

If a “glassy” coprecipitate is obtained following the

reference.
general procedure described in example 1, diethyl ether
In contrast, N-9 by itself is a viscous liquid which
is mixed with the residue. Upon evaporation of the
cannot be formulated as a powder in solid dosage forms
diethyl ether a crystalline powder is obtained.
such as tablets or capsules. N-9 has heretofore been 40
EXAMPLE 3
unable to form elegant tablets or capsules which are
preferred by the user cover creams and suppositories.
If a ?nely divided crystalline powder of the PVP

Additionally, at its generally accepted effective spermi
cidal concentrations (approximately 160 mg/ml), N-9 is
irritating to the vaginal epithelia and lining of the vagi

I/N-9 coprecipitate is desired, following the procedure
45

nal vault.
At concentrations below 550 ppm neither iodine nor
N-9 are known to irritate sensitive membrane linings of

crystalline powder is obtained by the freeze-drying step.

the human body. Thus, the coprecipitate powders can
be formulated into drug delivery systems that can re 50
lease their active ingredients in a predictable manner

without causing irritation to surrounding membrane

linings.

described in Example 1, the residue, received after
evaporation described in Example 1, is dissolved in a
mixture of methanol/ 1,4 dioxane (1:4 ratio v/v) and
subjected to freeze-drying for at least 12 hours. A fine
EXAMPLE 4

Commercially available nonoxynol-9 containing sev
enteen oligomers with an average molecular weight of
599 is utilized as a component in the general procedure

The powders of the invention are acceptable to the

described in Example 1. The oligomer of N-9 is isolated

user and furnish prolonged protection against AIDS
and sexually transmitted diseases (STDs) with minimal
absorption to the systemic circulation.
The main ingredient in the powders of the high en
ergy coprecipitates, described in this invention, is the
hydrophilic polymer PVP. This polymer, which exists
in the powders in a ratio of approximately forty parts to
one part of N-9, not only enhances the solubility of the

55 by the HPLC procedure disclosed in Walter, B. A. et a1.

(1988) Toxicol. Applied Pharmacol. 96: 258-268; Walter,
B. A. et al., (1991) Pharm. Res. 8: 409-411; and Walter,
B. A. et al., (1991) Pharm. Res. 8: 403-408, incorporated

herein by reference).
Brie?y, the separation is achieved by a preparative
Zorbax-NHZ column (250 mm, 7 pm, ><2l.l mm i.d.).

EXAMPLE 5
various N-9 oligomers but also contributes to the syner
gistic action of N-9 and iodine against the AIDS virus.
Stock solutions of N-9 (250 mg/ml) were prepared in
Thus, in a most important aspect of the invention, the 65 tetrahydrofuran. A 1.0 ml aliquot was separated on a
active ingredients (N-9 and iodine) are present in the
preparative Zorbax-NH2 7 pm column, 250 mm><2l.2
powder in such minuscule quantities that are known not
mm I.D., using a linear solvent gradient from 98%
to irritate membrane linings of the body.
A-2% B to 50% A—50% B in 90 min., where A=tet

13

5,380,523

14

rahydrofuranzhexane (20:80, v/v) and B=water:2

cipitate has antiviral activity against human im

propanol (10:90, v/v) delivered at 9.9 ml/min at ambi

munode?ciency virus-l (HIV-1) in an MT-2 assay.
2. A composition according to claim 1, wherein said
coprecipitate is a powder.
3. A composition according to claim 2, wherein said

ent temperature and detection at 280 nm. The HPLC
system used was a Waters HPLC system (Millipore,

Waters Chromatography Division, Millford, Mass.)
consisting of two Waters Model 510 HPLC pumps, a
Waters Model 680 gradient controller, a Waters Model
440 Absorbance detector (280 nm), and a Waters Model
SE120 dual channel recorder. Samples were introduced

powder is a ?nely divided crystalline powder.
4. A composition according to claim 1, wherein said
PVP-I comprises about 0.09—9.4% w/w of iodine.
5. A composition according to claim 1, wherein said

via a Rheodyne Model 7125 loop injector equipped

PVP-I comprises an antiviral concentration of free io
dine of about 0.03% w/v or 300 ppm complexed with
PVP.

with a 100 pl loop onto the HPLC column. Seventeen
oligomers were collected, concentrated and reinjected

6. A composition according to claim 1, wherein said

onto the analytical system for further puri?cation. The

PVP-I comprises an effective antiviral concentration of
free iodine of about 0.0094 w/v of iodine or 94 ppm

599 molecular weight fraction and 305 molecular
weight fraction were separated from the other fractions.
A 10% or 1% solution of w/v of PVP-I and the MW

complexed with PVP.
7. A composition according to claim 1, wherein said

599 fraction of the compound of nonoxynol-9 (N9)
nonoxynol oligomer of said coprecipitate comprises
(isolated as set forth above) in absolute ethanol (metha
from about 5.8 to 11.8% W/w of nonoxynol-9 oligomer.
nol) was made. Both solutions were added via dropping
funnels into a round bottom ?ask. It is important in this 20 8. A composition according to claim 1, wherein said
coprecipitate is present at a concentration of about 3.24
step to allow the dropping of the two solutions to con
mg/ml
of PVP-I and about 0.2 mg/ml of N-9 oligomer
tinue for 1.5 hours. Thus the addition of the two solu
of an average molecular weight of 599.
tions must take place slowly.
9. A composition according to claim 1, wherein said

To an oil bath which had been preheated to 100° C.,
the ?ask was placed and the solvent allowed to evapo
rate. It was important to make sure that the temperature

coprecipitate is present at a concentration of about 5.8

mg/ml PVP-I and about 0.2 mg/ml N-9 oligomer of an
average molecular weight of 306.
10. A composition according to claim 1 wherein said
coprecipitate is present at a concentration of about 5.8

was well controlled during the evaporation process.
The evaporation process should take between 1 and 2

hours. The evaporation should not take place longer
than 2 hours.

A high energy coprecipitate of the compounds is
obtained.
Examples 6-8 .show formulations of the high energy
coprecipitate of the invention.
EXAMPLE 6

ppm of N-9 oligomer and about 940 ppm of PVP-I or 94
30 ppm of iodine.

11. A composition of claim 1, wherein said nonoxynol
oligomer is an nonoxynol-9 oligomer with an average

molecular weight of 599.

oligomer is nonoxynol-9 oligomer comprising oligo

35 mers of N-9 having a range of molecular weight of each

A high energy coprecipitate composition of

oligomer from about 264 to about 1000.
13. A composition of claim 1, wherein the percent of
polyvinylpyrrolidone ranges from about 88% to about
97%.
14. A composition of claim 1, wherein the average

9.4-0.09% I w/w and ll.8-5.8% N-9 w/w. The high
energy coprecipitate provides anti-HIV protection at an
effective concentration of about 3.24 mg/mi of PVP-I
and 0.2 mg/ml of N-9 of an average molecular weight

molecular weight of said polyvinylpyrrolidone ranges

of 599 in a tablet formulation.

from about 2,500 to 1,100,000.
15. A method of preparing a composition according
to claim 1, comprising the steps of:

EXAMPLE 7

A high energy coprecipitate providing anti-HIV pro
tection at an effective concentration of about 5.8 mg/ml 45
PVP-I and 0.2 mg/ml N-9 of an average molecular

weight of 305 in a capsule formulation.

tection at an effective concentration of about 58 ppm of
N-9 and 940 ppm of PVP-I or 94 ppm of iodine in a

(a) fractionating commercially available spermicide
nonoxynol-9 (N-9) to seventeen oligomers by high

pressure liquid chromatography (HPLC);
(b) adding an N-9 oligomer obtained in step (a) with

EXAMPLE 8

A high energy coprecipitate providing anti-HIV pro

‘

12. A composition of claim 1, wherein said nonoxynol

a 10% or 1% solution w/v of PVP-I in a solvent,
50

(c) placing the product of step (b) in an oil bath at
about 100° C., and allowing the solvent to evapo
rate; and

The invention is not to be limited to the exact details

(d) obtaining a high energy coprecipitate of N-9,
polyvinylpyrrolidone (PVP) and iodine.

procedures or embodiments shown and described, as

comprising administering to said vaginal cavity of said

cream formulation.

16. A method of achieving a contraceptive and anti
of operation, or to the exact compositions, methods, 55 HIV in environment the vaginal cavity of a female

obvious modi?cations and equivalents will be apparent
to one skilled in the art. The invention is therefore to be

female an effective amount of a composition according
to claim 1 to achieve a contraceptive and anti-HIV in

limited only by the full scope which can be legally
environment the vaginal cavity of said female.
60
accorded to the appended claims.
17. The method according to claim 16, wherein said
We claim:
coprecipitate is administered in a form selected from the
1. A composition comprising a high energy coprecip
group consisting of tablets, capsules, ointments, creams

itate of nonoxynol oligomer and polyvinylpyrrolidone
and suppositories.
polymer and iodine, or polyvinylpyrrolidone-iodine
18. The method according to claim 16, wherein said
complex (PVP-I), wherein the combined effect of the 65 effective amount of said coprecipitate comprises from

compounds simultaneously precipitated in said high

energy coprecipitate exceeds the individual effect of
said compounds, and wherein said high energy copre

about 6-12% w/v N-9 and about 0.09—9% w/v of PVP
I.
*
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